Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 5/20 | 0.49 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 11/20 | 0.44 |
| ▸ | MMP3 | P08254 | 10/20 | 0.44 |
| ▸ | MMP1 | P03956 | 9/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807014 | 0.79 | CTSL (0.45) | CTSLCTSSCTSBMMP2MMP3 | |
| SCHEMBL7238076 | 0.78 | MMP2 (0.44) | CTSLCTSSCTSBMMP2MMP3 | |
| SCHEMBL6807292 | 0.77 | CDC7 (0.40) | CDC7DBF4CCNE1CDK2MMP2 | |
| SCHEMBL6806942 | 0.76 | CTSL (0.43) | CTSLCTSSCTSBMMP2MMP3 | |
| SCHEMBL6807089 | 0.75 | CDC7 (0.42) | CDC7DBF4CCNE1CDK2 | |
| SCHEMBL6801151 | 0.69 | CTSL (0.39) | CTSLCTSSCTSBMMP2MMP3 | |
| SCHEMBL30982345 | 0.68 | MME (0.67) | MMP2MMP3MMP1LTA4H | |
| SCHEMBL13073340 | 0.67 | EPHX2 (0.61) | MMP2MMP3MMP1 | |
| SCHEMBL7358712 | 0.67 | EPHX2 (0.61) | MMP2MMP3MMP1 | |
| SCHEMBL7144493 | 0.67 | EPHX2 (0.61) | MMP2MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730671-B2 | ENZYME INHIBITOR TREATING AUTOIMMUNE DISEASES, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-20030158406-A1 | Compounds useful as reversible inhibitors of cathepsin S | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| US-6608057-B2 | Compounds useful as reversible inhibitors of cathepsin S | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-19 | — | — | US | disclosed |
| US-20020091259-A1 | Compounds useful as reversible inhibitors of cathepsin S | CYWIN CHARLES L (US) | 2002-07-11 | — | — | US | disclosed |
| US-6395897-B1 | DRUGS FOR ENZYME INHIBITORS ANTICOAGULANTS AND TREATMENT OF AUTOIMMUNE DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091259-A1 | Compounds useful as reversible inhibitors of cathepsin S | CTSS, CTSB, CTSV | CDC7 1124/4885DBF4 4465/4885CCNE1 662/4885 |
| US-20030158406-A1 | Compounds useful as reversible inhibitors of cathepsin S | CTSS, CTSB, CTSV | CDC7 1124/4885DBF4 4465/4885CCNE1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.